Adverum Biotechnologies, Inc.
ADVM
$2.91
-$0.06-2.02%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -111.16% | 17.49% | 41.36% | 14.69% | 12.44% |
| Total Depreciation and Amortization | -19.72% | -41.02% | -37.68% | -37.37% | -41.06% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 121.04% | -69.61% | -54.84% | -14.44% | 74.58% |
| Change in Net Operating Assets | 330.86% | 187.00% | -187.65% | -125,933.33% | -157.68% |
| Cash from Operations | -32.45% | 11.66% | 14.65% | -3.72% | -15.44% |
| Capital Expenditure | 68.23% | 55.35% | 55.56% | -5.88% | -3.78% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 57.38% | -170.22% | -103.45% | -201.48% | -500.41% |
| Cash from Investing | 57.59% | -173.34% | -103.47% | -202.29% | -542.17% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -1.24% | -100.00% | -- | -- | 0.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 43.98% | 100.00% | -1,550.00% | -- | -31.40% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.73% | -492.17% | -150.90% | 8,587.83% | -94.01% |